表紙:ファーマコビジランスの世界市場:臨床試験別、方法別、タイプ別、エンドユーザー別の予測(2026年まで)- COVID-19の累積的影響
市場調査レポート
商品コード
996076

ファーマコビジランスの世界市場:臨床試験別、方法別、タイプ別、エンドユーザー別の予測(2026年まで)- COVID-19の累積的影響

Pharmacovigilance Market Research Report by Clinical Trial, by Method, by Type, by End User, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版日: | 発行: 360iResearch LLP | ページ情報: 英文 185 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.11円
ファーマコビジランスの世界市場:臨床試験別、方法別、タイプ別、エンドユーザー別の予測(2026年まで)- COVID-19の累積的影響
出版日: 2021年06月01日
発行: 360iResearch LLP
ページ情報: 英文 185 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のファーマコビジランスの市場規模は、2020年の56億9,823万米ドルから、2025年末までに95億3,087万米ドルに拡大すると予想されています。

COVID-19は、ほぼすべての業界に影響を与えた比類のない世界の公衆衛生上の緊急事態であるため、予測期間中に業界の成長に長期的な影響を与えると予測されています。

当レポートは、世界のファーマコビジランス市場について調査しており、市場の機会や課題、成長および抑制要因、COVID-19の累積的影響、臨床試験・方法・タイプ・エンドユーザー・地域別の市場分析、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 序文

  • 調査目的
  • 市場セグメンテーションとカバレッジ
  • 調査期間
  • 通貨と価格
  • 言語
  • 制約事項
  • 利害関係者

第2章 調査方法

  • 調査プロセス
    • 定義:調査目的
    • 決定:調査計画
    • 準備:調査機器
    • 収集:データソース
    • 分析:データの解釈
    • 策定:データ検証
    • 公開:調査レポート
    • 繰り返し:レポートの更新
  • 調査の実行
    • 開始:調査プロセス
    • 計画:調査計画を作成する
    • 実行:調査を実施する
    • 検証:発見と分析
    • 出版物:調査報告
  • 調査成果

第3章 エグゼクティブサマリー

  • 市場展望
  • タイプ別市場の展望
  • 方法別市場の展望
  • 臨床試験別市場の展望
  • エンドユーザー別市場の展望
  • 地域別市場の展望
  • 競合他社の展望

第4章 市場概要

  • COVID-19の累積的影響

第5章 市場の洞察

  • 市場力学
    • 成長要因
    • 抑制要因
    • 市場機会
    • 課題
  • ポーターのファイブフォース分析

第6章 臨床試験別市場

  • フェーズI
  • フェーズII
  • フェーズIII
  • フェーズIV
  • 前臨床

第7章 方法別市場

  • コホートイベントモニタリング
  • EHRマイニング
  • 強化されたADRレポート
  • 自発的な報告
  • ターゲットを絞った自発的なレポート

第8章 タイプ別市場

  • 外部委託
  • 社内

第9章 エンドユーザー別市場

  • 学術・研究機関
  • 政府機関
  • 健康保険会社
  • 病院およびケアプロバイダー

第10章 南北アメリカ市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋地域市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • 韓国
  • タイ

第12章 欧州、中東・アフリカ市場

  • フランス
  • ドイツ
  • イタリア
  • オランダ
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • FPNVポジショニングマトリックス
    • 象限
    • 事業戦略
    • 製品の満足度
  • 市場ランキング分析
  • 市場シェア分析
  • 競合他社のSWOT分析
  • 競合シナリオ
    • 合併・買収
    • 合意、コラボレーション、およびパートナーシップ
    • 新製品の発売と強化
    • 投資と資金調達
    • 評価、認知、拡大

第14章 企業プロファイル

  • Accenture, PLC
  • Bristol-Myers Squibb
  • C.H. Boehringer Sohn AG & Ko. KG
  • Capgemini SE
  • Clinquest Group B.V.
  • Covance Inc.
  • F. Hoffmann-La Roche AG
  • FMD K&L Inc
  • GlaxoSmithKline PLC
  • HCL Technologies
  • IBM Corporation
  • ICON PLC
  • Infosys Limited
  • IQVIA
  • ITclinical
  • Janssen Research & Development, LLC
  • Laboratory Corporation
  • Laboratory Corporation of America Holdings
  • Novartis International AG
  • Oracle Corporation
  • PAREXEL International
  • Pfizer Inc.
  • Quanticate International limited
  • Sanofi S.A.
  • Syneos Health
  • Take Solutions Ltd.
  • Tata Consultancy Services
  • Wipro Limited

第15章 付録

  • ディスカッションガイド
  • ライセンスと価格
図表

LIST OF FIGURES

  • FIGURE 1. GLOBAL PHARMACOVIGILANCE MARKET SIZE, 2020 VS 2026 (USD MILLION)
  • FIGURE 2. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2020 (USD MILLION)
  • FIGURE 3. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2020 (USD MILLION)
  • FIGURE 4. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2020 (USD MILLION)
  • FIGURE 5. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2020 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 7. GLOBAL PHARMACOVIGILANCE MARKET: MARKET DYNAMICS
  • FIGURE 8. GLOBAL PHARMACOVIGILANCE MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 9. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2020 VS 2026 (%)
  • FIGURE 10. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2020 VS 2026 (USD MILLION)
  • FIGURE 11. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2026
  • FIGURE 12. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE I, 2018-2026 (USD MILLION)
  • FIGURE 13. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE I, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 14. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE II, 2018-2026 (USD MILLION)
  • FIGURE 15. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE II, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 16. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE III, 2018-2026 (USD MILLION)
  • FIGURE 17. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE III, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 18. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE IV, 2018-2026 (USD MILLION)
  • FIGURE 19. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE IV, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 20. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRE-CLINICAL, 2018-2026 (USD MILLION)
  • FIGURE 21. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRE-CLINICAL, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 22. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2020 VS 2026 (%)
  • FIGURE 23. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2020 VS 2026 (USD MILLION)
  • FIGURE 24. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2026
  • FIGURE 25. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COHORT EVENT MONITORING, 2018-2026 (USD MILLION)
  • FIGURE 26. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COHORT EVENT MONITORING, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 27. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY EHR MINING, 2018-2026 (USD MILLION)
  • FIGURE 28. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY EHR MINING, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 29. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY INTENSIFIED ADR REPORTING, 2018-2026 (USD MILLION)
  • FIGURE 30. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY INTENSIFIED ADR REPORTING, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 31. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SPONTANEOUS REPORTING, 2018-2026 (USD MILLION)
  • FIGURE 32. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SPONTANEOUS REPORTING, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 33. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TARGETED SPONTANEOUS REPORTING, 2018-2026 (USD MILLION)
  • FIGURE 34. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TARGETED SPONTANEOUS REPORTING, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 35. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2020 VS 2026 (%)
  • FIGURE 36. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2020 VS 2026 (USD MILLION)
  • FIGURE 37. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2026
  • FIGURE 38. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CONTRACT OUTSOURCING, 2018-2026 (USD MILLION)
  • FIGURE 39. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CONTRACT OUTSOURCING, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 40. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY IN-HOUSE, 2018-2026 (USD MILLION)
  • FIGURE 41. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY IN-HOUSE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 42. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2020 VS 2026 (%)
  • FIGURE 43. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2020 VS 2026 (USD MILLION)
  • FIGURE 44. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2026
  • FIGURE 45. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2026 (USD MILLION)
  • FIGURE 46. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 47. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2026 (USD MILLION)
  • FIGURE 48. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY GOVERNMENT AGENCIES, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 49. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY HEALTH INSURANCE COMPANIES, 2018-2026 (USD MILLION)
  • FIGURE 50. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY HEALTH INSURANCE COMPANIES, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 51. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY HOSPITALS & CARE PROVIDERS, 2018-2026 (USD MILLION)
  • FIGURE 52. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY HOSPITALS & CARE PROVIDERS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 53. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 54. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 55. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 56. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 57. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 58. CANADA PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 59. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 60. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 61. CALIFORNIA PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 62. FLORIDA PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 63. ILLINOIS PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 64. NEW YORK PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 65. OHIO PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 66. PENNSYLVANIA PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 67. TEXAS PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 68. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 69. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 70. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 71. CHINA PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 72. INDIA PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 73. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 74. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 75. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 76. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 77. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 78. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 79. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 80. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 81. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 82. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 83. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 84. ITALY PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 85. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 86. QATAR PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 87. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 88. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 89. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 90. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 91. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 92. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 93. GLOBAL PHARMACOVIGILANCE MARKET: FPNV POSITIONING MATRIX
  • FIGURE 94. GLOBAL PHARMACOVIGILANCE MARKET: SHARE, BY QUADRANT, 2020
  • FIGURE 95. GLOBAL PHARMACOVIGILANCE MARKET: SHARE, BY COMPANY, 2020
  • FIGURE 96. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL PHARMACOVIGILANCE MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL PHARMACOVIGILANCE MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE I, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE II, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE III, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE IV, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 8. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRE-CLINICAL, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 9. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 10. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COHORT EVENT MONITORING, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 11. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY EHR MINING, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 12. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY INTENSIFIED ADR REPORTING, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 13. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SPONTANEOUS REPORTING, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 14. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TARGETED SPONTANEOUS REPORTING, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 15. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 16. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CONTRACT OUTSOURCING, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 17. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY IN-HOUSE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 18. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 19. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 20. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY GOVERNMENT AGENCIES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 21. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY HEALTH INSURANCE COMPANIES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 22. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY HOSPITALS & CARE PROVIDERS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 23. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 24. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 25. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 26. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 27. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 28. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 29. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 30. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 31. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 32. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 33. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 34. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 35. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 36. CANADA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 37. CANADA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 38. CANADA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 39. CANADA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 40. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 41. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 42. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 43. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 44. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 45. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 46. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 47. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 48. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 49. CALIFORNIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 50. CALIFORNIA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 51. CALIFORNIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 52. CALIFORNIA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 53. FLORIDA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 54. FLORIDA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 55. FLORIDA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 56. FLORIDA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 57. ILLINOIS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 58. ILLINOIS PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 59. ILLINOIS PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 60. ILLINOIS PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 61. NEW YORK PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 62. NEW YORK PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 63. NEW YORK PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 64. NEW YORK PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 65. OHIO PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 66. OHIO PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 67. OHIO PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 68. OHIO PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 69. PENNSYLVANIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 70. PENNSYLVANIA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 71. PENNSYLVANIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 72. PENNSYLVANIA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 73. TEXAS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 74. TEXAS PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 75. TEXAS PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 76. TEXAS PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 77. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 78. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 79. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 80. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 81. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 82. CHINA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 83. CHINA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 84. CHINA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 85. CHINA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 86. INDIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 87. INDIA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 88. INDIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 89. INDIA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 90. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 91. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 92. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 93. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 94. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 95. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 96. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 97. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 98. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 99. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 100. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 101. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 102. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 103. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 104. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 105. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 106. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 107. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 108. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 109. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 110. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 111. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 112. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 113. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 119. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 120. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 121. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 122. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 123. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 124. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 125. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 126. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 127. ITALY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 128. ITALY PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 129. ITALY PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 130. ITALY PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 131. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 132. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 133. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 134. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 135. QATAR PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 136. QATAR PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 137. QATAR PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 138. QATAR PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 139. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 140. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 141. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 142. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 143. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 144. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 145. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 146. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 147. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 148. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 149. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 150. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 151. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 152. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 153. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 154. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 155. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 156. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 157. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 158. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 159. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 160. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 161. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 162. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 163. GLOBAL PHARMACOVIGILANCE MARKET: SCORES
  • TABLE 164. GLOBAL PHARMACOVIGILANCE MARKET: BUSINESS STRATEGY
  • TABLE 165. GLOBAL PHARMACOVIGILANCE MARKET: PRODUCT SATISFACTION
  • TABLE 166. GLOBAL PHARMACOVIGILANCE MARKET: RANKING
  • TABLE 167. GLOBAL PHARMACOVIGILANCE MARKET: SHARE, BY QUADRANT, 2020
  • TABLE 168. GLOBAL PHARMACOVIGILANCE MARKET: SHARE, BY COMPANY, 2020
  • TABLE 169. GLOBAL PHARMACOVIGILANCE MARKET: MERGER & ACQUISITION
  • TABLE 170. GLOBAL PHARMACOVIGILANCE MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 171. GLOBAL PHARMACOVIGILANCE MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 172. GLOBAL PHARMACOVIGILANCE MARKET: INVESTMENT & FUNDING
  • TABLE 173. GLOBAL PHARMACOVIGILANCE MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 174. GLOBAL PHARMACOVIGILANCE MARKET: LICENSE & PRICING
  • TABLE 175. GLOBAL PHARMACOVIGILANCE MARKET: CONTACT DETAILS
目次
Product Code: MRR-43676CF420AF

The Global Pharmacovigilance Market size was estimated at USD 5,698.22 Million in 2020 and expected to reach USD 6,344.14 Million in 2021, at a Compound Annual Growth Rate (CAGR) 11.67% to reach USD 11,052.18 Million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Pharmacovigilance to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Clinical Trial, the Pharmacovigilance Market was studied across Phase I, Phase II, Phase III, Phase IV, and Pre-clinical.

Based on Method, the Pharmacovigilance Market was studied across Cohort Event Monitoring, EHR Mining, Intensified ADR Reporting, Spontaneous Reporting, and Targeted Spontaneous Reporting.

Based on Type, the Pharmacovigilance Market was studied across Contract Outsourcing and In-house.

Based on End User, the Pharmacovigilance Market was studied across Academic & Research Institutes, Government Agencies, Health Insurance Companies, and Hospitals & Care Providers.

Based on Geography, the Pharmacovigilance Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Pharmacovigilance Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Pharmacovigilance Market, including Accenture, PLC, Bristol-Myers Squibb, C.H. Boehringer Sohn AG & Ko. KG, Capgemini SE, Clinquest Group B.V., Covance Inc., F. Hoffmann-La Roche AG, FMD K&L Inc, GlaxoSmithKline PLC, HCL Technologies, IBM Corporation, ICON PLC, Infosys Limited, IQVIA, ITclinical, Janssen Research & Development, LLC, Laboratory Corporation, Laboratory Corporation of America Holdings, Novartis International AG, Oracle Corporation, PAREXEL International, Pfizer Inc., Quanticate International limited, Sanofi S.A., Syneos Health, Take Solutions Ltd., Tata Consultancy Services, and Wipro Limited.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Pharmacovigilance Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Pharmacovigilance Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Pharmacovigilance Market?
  • 4. What is the competitive strategic window for opportunities in the Global Pharmacovigilance Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Pharmacovigilance Market?
  • 6. What is the market share of the leading vendors in the Global Pharmacovigilance Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Pharmacovigilance Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Type Outlook
  • 3.4. Method Outlook
  • 3.5. Clinical Trial Outlook
  • 3.6. End User Outlook
  • 3.7. Geography Outlook
  • 3.8. Competitor Outlook

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in the prevalence of chronic diseases
      • 5.1.1.2. Rise in pharmacovigilance application in spontaneous reporting and electronic health record (EHR) mining
      • 5.1.1.3. Rise in demand for outsourcing services by players
      • 5.1.1.4. Rising incidence of ADR and drug toxicity
    • 5.1.2. Restraints
      • 5.1.2.1. High-cost technology for small and mid-sized player
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of COVDI-19 have opened new opportunities
      • 5.1.3.2. Rising investment in R&D by healthcare companies
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of skilled labor
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Porters Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Pharmacovigilance Market, by Clinical Trial

  • 6.1. Introduction
  • 6.2. Phase I
  • 6.3. Phase II
  • 6.4. Phase III
  • 6.5. Phase IV
  • 6.6. Pre-clinical

7. Pharmacovigilance Market, by Method

  • 7.1. Introduction
  • 7.2. Cohort Event Monitoring
  • 7.3. EHR Mining
  • 7.4. Intensified ADR Reporting
  • 7.5. Spontaneous Reporting
  • 7.6. Targeted Spontaneous Reporting

8. Pharmacovigilance Market, by Type

  • 8.1. Introduction
  • 8.2. Contract Outsourcing
  • 8.3. In-house

9. Pharmacovigilance Market, by End User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Government Agencies
  • 9.4. Health Insurance Companies
  • 9.5. Hospitals & Care Providers

10. Americas Pharmacovigilance Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States
    • 10.6.1. California
    • 10.6.2. Florida
    • 10.6.3. Illinois
    • 10.6.4. New York
    • 10.6.5. Ohio
    • 10.6.6. Pennsylvania
    • 10.6.7. Texas

11. Asia-Pacific Pharmacovigilance Market

  • 11.1. Introduction
  • 11.2. China
  • 11.3. India
  • 11.4. Indonesia
  • 11.5. Japan
  • 11.6. Malaysia
  • 11.7. Philippines
  • 11.8. South Korea
  • 11.9. Thailand

12. Europe, Middle East & Africa Pharmacovigilance Market

  • 12.1. Introduction
  • 12.2. France
  • 12.3. Germany
  • 12.4. Italy
  • 12.5. Netherlands
  • 12.6. Qatar
  • 12.7. Russia
  • 12.8. Saudi Arabia
  • 12.9. South Africa
  • 12.10. Spain
  • 12.11. United Arab Emirates
  • 12.12. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
    • 13.1.1. Quadrants
    • 13.1.2. Business Strategy
    • 13.1.3. Product Satisfaction
  • 13.2. Market Ranking Analysis
  • 13.3. Market Share Analysis, By Quadrant
  • 13.4. Market Share Analysis, By Company
  • 13.5. Competitive Scenario
    • 13.5.1. Merger & Acquisition
    • 13.5.2. Agreement, Collaboration, & Partnership
    • 13.5.3. New Product Launch & Enhancement
    • 13.5.4. Investment & Funding
    • 13.5.5. Award, Recognition, & Expansion

14. Company Usability Profiles

  • 14.1. Accenture, PLC
  • 14.2. Bristol-Myers Squibb
  • 14.3. C.H. Boehringer Sohn AG & Ko. KG
  • 14.4. Capgemini SE
  • 14.5. Clinquest Group B.V.
  • 14.6. Covance Inc.
  • 14.7. F. Hoffmann-La Roche AG
  • 14.8. FMD K&L Inc
  • 14.9. GlaxoSmithKline PLC
  • 14.10. HCL Technologies
  • 14.11. IBM Corporation
  • 14.12. ICON PLC
  • 14.13. Infosys Limited
  • 14.14. IQVIA
  • 14.15. ITclinical
  • 14.16. Janssen Research & Development, LLC
  • 14.17. Laboratory Corporation
  • 14.18. Laboratory Corporation of America Holdings
  • 14.19. Novartis International AG
  • 14.20. Oracle Corporation
  • 14.21. PAREXEL International
  • 14.22. Pfizer Inc.
  • 14.23. Quanticate International limited
  • 14.24. Sanofi S.A.
  • 14.25. Syneos Health
  • 14.26. Take Solutions Ltd.
  • 14.27. Tata Consultancy Services
  • 14.28. Wipro Limited

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing
  • 15.3. Contact Details